Insights on Biohaven’s New Phase 2/3 Trial of Potassium Inhibitor BHV-7000 for Treating Focal Epilepsy

Published Date: 05 Sep 2024

Principal investigator Aliza Alter, MD, a pediatric neurologist at the Institute of Neurology in Livingston, New Jersey, provided commentary on a newly initiated phase 2/3 study assessing BHV-7000 as an antiseizure medication.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Long Wait Times on the Other Side of the Pond: King Charles' Cancer Diagnosis.

2.

recognizing the mechanism by which the replication of the host cell is outperformed by the skin cancer virus.

3.

FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.

4.

Durvalumab Wins FDA Approval in Limited-Stage SCLC

5.

Telehealth in the pandemic era resulted in fewer therapy interruptions.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot